Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Feb;17(1):58-65.
doi: 10.1111/j.1755-5949.2010.00211.x. Epub 2010 Nov 21.

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease

Yukihiro Ohno  1
Affiliations
Review

Therapeutic role of 5-HT1A receptors in the treatment of schizophrenia and Parkinson's disease

Yukihiro Ohno. CNS Neurosci Ther. 2011 Feb.

Abstract

5-HT(1A) receptors have long been implicated in the pathogenesis and treatment of anxiety and depressive disorders. Recently, several lines of studies have revealed new insights into the therapeutic role of 5-HT(1A) receptors in treating schizophrenia and Parkinson's disease. Specifically, 5-HT(1A) receptors seem to be a promising target for alleviating antipsychotic-induced extrapyramidal side effects (EPS) and cognitive/affective disorders in schizophrenia. In the treatment of patients with Parkinson's disease, 5-HT(1A) agonists are expected to improve not only affective symptoms (e.g., anxiety and depression), but also the core parkinsonian symptoms as well as antiparkinsonian agents-induced side effects (e.g., L-DOPA-induced dyskinesia). Here, the therapeutic mechanisms mediated by 5-HT(1A) receptors in schizophrenia and Parkinson's disease are reviewed. This evidence should encourage discovery of new 5-HT(1A) ligands, which can resolve the unmet clinical needs in the current therapy.

PubMed Disclaimer

Conflict of interest statement

The author has no conflict of interest with any commercial or other associations in connection with the submitted article.

Figures

Figure 1
Figure 1
Signal transduction pathways of 5‐HT1A receptor (A) and the mechanism underlying anxiolytic and antidepressant actions of 5‐HT1A agonists (B). GIRK, G‐protein‐gated inwardly rectifying potassium channel; PK A, protein kinase A.
Figure 2
Figure 2
Current therapeutics, unmet clinical needs and therapeutic role of 5‐HT1A receptors in the treatment of schizophrenia.
Figure 3
Figure 3
Therapeutic mechanisms and action sites of 5‐HT1A agonists and 5‐HT2A antagonists in ameliorating the extrapyramidal motor disorders. DA, dopamine; Glu, glutamate; (+), excitation; (−), inhibition.
Figure 4
Figure 4
Current therapeutics, unmet clinical needs and therapeutic role of 5‐HT1A receptors in the treatment of Parkinson's disease. AADCI, aromatic L‐amino acid decarboxylase inhibitors; ACh, acetylcholine; MAO‐B, monoamine oxidase‐B; COMT, catechol‐O‐methyltransferase.
See this image and copyright information in PMC

References

    1. Roth BL. Multiple serotonin receptors: Clinical and experimental aspects. Ann Clin Psychiatry 1994;6:67–78. - PubMed
    1. Baumgarten HG, Grozdanovic Z. Psychopharmacology of central serotonergic systems. Pharmacopsychiatry 1995;28:73–79. - PubMed
    1. Feighner JP, Boyer WF. Serotonin‐1A anxiolytics: An overview. Psychopathology 1989;22(Suppl 1):21–26. - PubMed
    1. Fuller RW. Role of serotonin in therapy of depression and related disorders. J Clin Psychiatry 1991;152(Suppl l):52–57. - PubMed
    1. Ohno Y. Tandospirone citrate, a new serotonergic anxiolytic agent: A potential use in Parkinson's disease In: Mizuno Y, Fisher A, Hanin I, editors. Mapping the progress of Alzheimer's and Parkinson's Disease. New York : Kluwer Academic/Plenum, 2002;423–428.

MeSH terms

Substances